Showing results (1-10 of 420) with videos related to

Sort By:
Pageof 42
Journal of the National Cancer Institute. Monographs|January 1, 1993
Taxol in malignant melanomaP H Wiernik, A I Einzig
Cancer Investigation|January 1, 1991
Phase II trial of taxol in patients with metastatic renal cell carcinomaA I Einzig, E Gorowski, J Sasloff, et al.
Investigational New Drugs|January 1, 1995
Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) resultsA I Einzig, S Lipsitz, P H Wiernik, et al.
American Journal of Clinical Oncology|February 20, 1999
Non-Hodgkin lymphoma in acquired immunodeficiency syndrome manifesting as bilateral hypopyonN A Jan, A I Einzig, M J Suhrland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinomaA I Einzig, P H Wiernik, J Sasloff, et al.
Medical Oncology (Northwood, London, England)|June 1, 1996
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapyA I Einzig, L M Schuchter, A Recio, et al.
Cancer|February 15, 1993
Taxol in ovarian cancerC D Runowicz, P H Wiernik, A I Einzig, et al.
The Cancer Journal From Scientific American|August 5, 1998
Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's diseaseP H Wiernik, J P Dutcher, A I Einzig, et al.
American Journal of Clinical Oncology|February 1, 1988
Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinomaS Wadler, A I Einzig, J P Dutcher, et al.
Investigational New Drugs|September 18, 1998
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancyA I Einzig, P H Wiernik, S Wadler, et al.
Pageof 42